The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 29.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
Apollomics Inc APLM
Outside both standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
read at $18.52
Apollomics Inc holds its Markup at $18.52.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 13 days |
| Price | $18.52 |
| Valuation | N/A trailing · -28.49 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.44 |
The business, in plain words · what the numbers mean
| Forward P/E | -28.5x |
| Profit margin | -123.7% currently unprofitable |
| Return on equity | -1,305.4% not currently earning a positive return on equity |
| Current ratio | 0.96 below 1 — short-term bills exceed liquid assets |
| Beta | 1.44 moves a little more than the market |
| Market cap | $41M |
| Employees | 14 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in APLM's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 30%.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $14.65 | -6.0% | · | $940 | -6.0% |
| 2 months | $13.60 | +1.3% | · | $1,013 | +1.3% |
| 3 months | $19.80 | -30.5% | · | $696 | -30.5% |
| 6 months | $16.71 | -17.6% | · | $824 | -17.6% |
| 1 year | $6.74 | +104.3% | · | $2,043 | +104.3% |
| 2 years | $23.10 | -40.4% | · | $596 | -40.4% |
| 3 years | $501.00 | -97.3% | · | $28 | -97.3% |
Historical returns from market close data. Past performance does not guarantee future results.